MN33-63

MN33-63 potently inhibits the proliferation of HCT-15, HeLa, HepG2, A549, HGC-27 and CT26 cancer cells, with an IC₅₀ range of 0.05 nM-306.10 nM at 72 h, and exhibits the strongest activity against HGC-27 cells^[1].
MN33-63 (100 nM; 24-48 h) potently inhibits the migration of CT26 cells, resulting in a migration rate of 2.51% at 24 h and 4.42% at 48 h^[1].
MN33-63 (100 nM; 48 h) induces strong G2/M phase arrest in CT26 cells, with 59.8% of cells residing in the G2/M phase after 48 h of incubation^[1].
MN33-63 (100 nM; 48 h) induces apoptosis in 61.10% of CT26 cells, and after 48 h of incubation, its pro-apoptotic activity is stronger than that of chlormethine hydrochloride (HY-B1253) (CH), SN-38 (HY-13704), or their physical mixture^[1].
MN33-63 (1-10000 nM, 1 μM; 72 h) reduces Topo I protein levels in CT26 cells in a dose-dependent manner within 72 h. Its inhibitory effect is significant at the concentration of 1 μM, and is superior to that of SN-38, CH and their physical mixture^[1].
MN33-63 (1 μM; 72 h) downregulates Bcl-2 expression and reduces the total caspase-3 protein level in CT26 cells, thereby activating the intrinsic apoptotic pathway^[1].
MN33-63 (1 μM + 2 μM MG132 (HY-13259); 1 μM + 50 μM chloroquine; 72 h) promotes the degradation of Topo I in CT26 cells via both the ubiquitin-proteasome and autophagy-lysosome pathways; after 72 h of incubation, MG132 and chloroquine reverse the reduction of Topo I^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.